Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,059 people get ARRY articles and Market Currents by email alert.

Get email alerts on ARRY »

ARRY

Array BioPharma Inc.

5/23/2013, 7:27 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Monday, May 6, 4:07 PM Array Biopharma (ARRY): Q1 EPS of -$0.19 misses by $0.05. Revenue of $10M misses by $4.54M. (PR) Comment! [Earnings, Breaking News]
Monday, May 6, 12:10 AM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Sunday, May 5, 5:35 PM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Thursday, April 4, 8:53 AM Array BioPharma's (ARRY +2.25%) ARRY-520 drug for multiple myeloma showed encouraging clinical activity in two trials of patients who had received heavy previous treatments and had "limited therapeutic options." The median survival rates was 19 months and the overall response rate 16%, similar to other recently approved products. ARRY-520 was also well tolerated. (PR) Comment! [Healthcare]
Wednesday, March 27, 6:13 PM Array Biopharma (ARRY) says it's entered into a sales agreement for an at-the-market share offering with Cantor Fitzgerald. Subject to the terms and conditions, ARRY] may from time to time issue and sell through Cantor up to $75M in stock. Shares -5% AH. Comment! [On the Move, Healthcare]
Wednesday, March 27, 5:49 PM After-hours top gainers, as of 5:15 p.m.: GBX +3%. GNW +3%. LCC +3%. MATX +1.4%. SU +1.1%.
After-hours top losers: ARRY -12%. RHT -9%. FIVE -7%. ESI -6%. PVH -5%. Comment! [On the Move]
Monday, March 25, 10:52 AM Array BioPharma (ARRY +11%) gets a big boost from an upgrade to Overweight at Piper Jaffray this morning, pushing the stock near a 5-month high. Piper says the company has a host of potentially positive study data due out later this year, and several partnering opportunities in FY13 that could bring in non-dilutive funding. This is encouraging, as the company already finished 2012 with $110M of cash, which the firm estimates would get ARRY through mid-2014. Comment! [Healthcare, On the Move]
Monday, February 4, 5:15 PM More on Array Biopharma (ARRY): Q2 beats as per share losses come in less-than-expected. CEO Ron Squarer notes strong progress across its pipeline, with Novartis saying it's set to begin Phase 3 trials of MEK162, and AstraZeneca set to start Phase 3 trials with selumetinib in non-small cell lung cancer during the second half of 2013. Comment! [Healthcare, Earnings]
Monday, February 4, 4:53 PM Array Biopharma (ARRY): FQ2 EPS of -$0.1 beats by $0.04. Revenue of $18.4M beats by $1.88M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 4, 12:10 AM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
Sunday, February 3, 5:35 PM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
Wednesday, November 21, 2012, 5:39 PM After-hours top gainers, as of 5:15 p.m.: IMGN +7.1%. SHLD +4.2%. ARRY +3.4%. IDIX +3.0%. VRTX +2.5%.
After-hours top losers: MRGE -9.0%. CVGI -7.1%. GORO -6.6%. HW -6.3%. QLIK -4.5%. 2 Comments [On the Move]
Friday, November 9, 2012, 10:39 AM Drug developer Array BioPharma (ARRY -12.3%) slides after pricing an 18M share secondary offering at $3.65 per share, a 10% discount to yesterday's close. The company had 95.4M shares outstanding as of October, which would make the sale nearly a 19% dilution to its float. Comment! [Healthcare, On the Move]
Friday, November 9, 2012, 9:10 AM Premarket gainers: ZIP +27%. KYAK +26%. LGF +9%. ENR +8%. PSTI +8%. IGT +7%. WCRX +6%. ISIS +5%.
Losers: GRPN -23%. MTG -15%. ARRY -12%. PGRX -12%. SPRD -10%. JCP -8%. PVR -6%. CPIX -5%. DIS -5%. 1 Comment [On the Move]
Friday, August 31, 2012, 4:15 PM Array BioPharma (ARRY) announces that Francis Bullock, Ph.D., and Kevin Koch, Ph.D., have decided not to stand for reelection to its Board of Directors and that David Snitman, Ph.D., intends to resign from the Board. Comment! [Healthcare]